Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExoFlo for COVID-19 Associated ARDS
NCT04493242Phase 2Completed
- Sponsor
- Direct Biologics
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of bone marrow mesenchymal stem cell derived extracellular vesicles in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Direct Biologics. Started Sep 2020; status: completed.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04493242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493242.